Jefferies Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Jefferies Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$22.2M	Sell	280,200 -461,700	-62%	-$38.9M	0.19%	84
2022 Q2	$55.1M	Sell	741,900 -1,186,900	-62%	-$89.1M	0.46%	33
2022 Q1	$173M	Buy	1,928,800 +1,543,100	+400%	+$142M	1.09%	15
2021 Q4	$43.2M	Sell	385,700 -201,600	-34%	-$24.3M	0.25%	58
2021 Q3	$73.8M	Buy	587,300 +472,300	+411%	+$60.8M	0.54%	25
2021 Q2	$15.6M	Sell	115,000 -438,600	-79%	-$57.7M	0.1%	164
2021 Q1	$75.1M	Sell	553,600 -271,600	-33%	-$40.7M	0.66%	19
2020 Q4	$116M	Buy	825,200 +283,000	+52%	+$36.2M	0.91%	17
2020 Q3	$60.4M	Sell	542,200 -496,700	-48%	-$55.7M	0.67%	17
2020 Q2	$116K	Buy	1,038,900 +573,500	+123%	+$56.5M	1.37%	9
2020 Q1	$36M	Sell	465,400 -59,600	-11%	-$5.28M	0.4%	25
2019 Q4	$49.9M	Sell	525,000 -369,200	-41%	-$31.9M	0.39%	37
2019 Q3	$68.2M	Buy	894,200 +394,200	+79%	+$32.8M	0.53%	14
2019 Q2	$43.9M	Sell	500,000 -1,827,300	-79%	-$156M	0.32%	35
2019 Q1	$211M	Buy	2,327,300 +873,200	+60%	+$74.3M	1.73%	7
2018 Q4	$104M	Buy	1,454,100 +456,700	+46%	+$36.8M	0.85%	13
2018 Q3	$95.6M	Sell	997,400 -1,323,900	-57%	-$128M	0.63%	17
2018 Q2	$221M	Buy	2,321,300 +1,636,300	+239%	+$150M	1.24%	10
2018 Q1	$60.1M	Sell	685,000 -254,400	-27%	-$23.2M	0.32%	34
2017 Q4	$79.7M	Buy	939,400 +924,000	+6,000%	+$77.4M	0.37%	31
2017 Q3	$1.33M	Sell	15,400 -838,900	-98%	-$67.3M	0.01%	1150
2017 Q2	$65.9M	Buy	854,300 +419,300	+96%	+$29.7M	0.44%	25
2017 Q1	$30.2M	Buy	435,000 +413,800	+1,952%	+$27.8M	0.22%	65
2016 Q4	$1.25M	Sell	21,200 -108,800	-84%	-$6.72M	0.01%	1149
2016 Q3	$8.62M	Sell	130,000 -37,700	-22%	-$2.33M	0.04%	361
2016 Q2	$9.07M	Buy	167,700 +36,500	+28%	+$2M	0.04%	308
2016 Q1	$6.78M	Buy	131,200 +46,900	+56%	+$2.44M	0.04%	382
2015 Q4	$5.92M	Sell	84,300 -144,200	-63%	-$9.84M	0.03%	398
2015 Q3	$14.2M	Buy	+228,500	New	+$18M	0.08%	187

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Jefferies Group's XBI Position: Q3 2022 in Review

Jefferies Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 93% in Q3 2022, selling an estimated $35.8M and leaving 31,002 shares worth $2.46M. The position accounts for 0.02% of the portfolio, ranked #535.

Jefferies Group first reported a position in XBI in Q3 2014 and has held it in 31 quarters since. The position peaked at $65.5M in Q1 2022. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Jefferies Group held 31,002 shares of State Street SPDR S&P Biotech ETF worth $2.46M as of Q3 2022.
Jefferies Group sold 424,343 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $35.8M.
State Street SPDR S&P Biotech ETF made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #535 holding.
Jefferies Group first reported a position in State Street SPDR S&P Biotech ETF in Q3 2014 and has held it in 31 quarters since.
Jefferies Group's State Street SPDR S&P Biotech ETF position peaked at $65.5M in Q1 2022.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.